If confirmed in vivo, for example through the generation of “humanized” mice models carrying N308K/A313S, these finding could highlight the importance of targeting SIRT6 pharmacology with compounds differentially targeting its multiple enzymatic activities to regulate the co-morbidities associated with obesity. The gene discussed is SIRT6; the disease is obesity disorder.